Sujana Biotech is developing a new set of therapeutics targeted at inflammatory and vascular disorders. The programs are based on research from Daniel Simon (University Hospitals Harrington Heart & Vascular Institute), Edward Plow (Cleveland Clinic), and Yunmei Wang (Case Western Reserve University). BioMotiv is cited as providing the scientific backing; BioMotiv is the for‑profit affiliate of University Hospitals’ Harrington Project, which aims to accelerate commercialization of research. The company is in an early financing stage and has raised $800,000 toward a planned $5 million round, according to a regulatory filing. No operating metrics (revenue/users) are disclosed in the article. Calls to Sujana Biotech and BioMotiv were not returned, and further details on programs, timelines, or partners were not provided in the piece.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

May 2015